首页> 外文期刊>International Urology and Nephrology >Investigative clinical study on prostate cancer: on the role of the pretreatment total PSA to free testosterone ratio in selecting different biology groups of prostate cancer patients.
【24h】

Investigative clinical study on prostate cancer: on the role of the pretreatment total PSA to free testosterone ratio in selecting different biology groups of prostate cancer patients.

机译:前列腺癌的临床研究研究:预处理总PSA与游离睾丸激素之比在选择前列腺癌患者不同生物学组中的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To show that prostate cancer biology is related to serum levels of both free testosterone (FT) and prostate-specific antigen (PSA), that PSA level is linearly related to FT and that the PSA to FT ratio may be considered as the growth rate parameter expressing cancer phenotype biology. MATERIALS AND METHODS: The study includes 135 consecutive patients diagnosed with prostate cancer. Pretreatment simultaneous serum samples for analyzing total testosterone (TT), FT and total PSA levels were obtained. The study was assessed according to a multidimensional approach of the five continuous variables including TT, FT, PSA, AGE and percentage of positive biopsies (=P+). The all sets of data were considered as one--sample with no groupings among the observations. Multivariate analysis included factor analysis (FA) and principal component analysis (PCA). Multivariate inferential statistics for comparing different groups of patients according to the PSA to free testosterone ratio (PSA/FT) included Hotteling's multivariate two-sample T(2)-Test for comparing two mean vectors as well as Box's M-Test with the chi-square approximation for comparing multiple covariance matrices when patients were sampled in more than two groups. RESULTS: Factor analysis showed the two natural grouping of variables, FT-TT and PSA-P+. PCA assessed FT and PSA as the two variables with large variances having a notable influence on the first two principal components. Multiple linear regression analysis showed that all the income variables, except age, significantly predicted the PSA/FT ratio. Patients were first sampled according to the PSA/FT ratio in group 1 (PSA/FT 0.20), and Hotteling's multivariate two sample T(2)-Test was significant (P < 0.01). Patients were then sampled according to the PSA/FT ratio in group 1 (PSA/FT 0.20 and 0.40), and Box's M-Test comparing the covariance matrices of the 3 groups differed significantly (P < 0.001). Finally, patients were sampled according to the PSA/FT ratio in 6 groups, and Box's M-Test was again significant (P < 0.001). CONCLUSIONS: The PSA to FT ratio is the growing rate parameter expressing different biology patterns and assessing different groups of prostate cancer patients. In our opinion, the results of the present study might have wide applications in understanding, assessing and planning prostate cancer studies including basic science, screening, assessing risk of the disease, predicting disease stage as well natural history after a planned treatment involving biochemical recurrence, progression, hormone refractory prostate cancer and disease-specific survival.
机译:目的:显示前列腺癌生物学与血清游离睾丸激素(FT)和前列腺特异性抗原(PSA)水平相关,PSA水平与FT呈线性相关,并且PSA与FT的比率可以视为增长速率参数表达癌症表型生物学。材料与方法:该研究包括135位连续被诊断为前列腺癌的患者。获得了用于分析总睾丸激素(TT),FT和总PSA水平的预处理同时血清样品。根据五个连续变量(包括TT,FT,PSA,AGE和活检阳性率(= P +))的多维方法对研究进行了评估。所有数据集都被视为一个样本,在观察值之间没有分组。多变量分析包括因素分析(FA)和主成分分析(PCA)。根据PSA与游离睾丸激素比率(PSA / FT)比较不同患者组的多元推论统计数据包括Hotteling的多元两样本T(2)-Test用于比较两个均值向量以及Box's M-Test与chi-在两组以上患者中进行抽样时,用于比较多个协方差矩阵的平方近似。结果:因子分析显示了两个自然的变量分组,即FT-TT和PSA-P +。 PCA将FT和PSA评估为两个变量,方差较大,对前两个主成分有显着影响。多元线性回归分析显示,除年龄外,所有收入变量均显着预测了PSA / FT比率。首先根据第1组(PSA / FT 0.20)中的PSA / FT比对患者进行采样,然后Hotteling的多变量两个样本T(2)-检验显着(P < 0.01)。然后根据第1组(PSA / FT 0.20和 0.40)的PSA / FT比对患者进行采样,与Box的M检验比较3组的协方差矩阵有显着差异(P <0.001)。最后,根据PSA / FT比对患者进行了6组采样,Box的M检验再次显着(P <0.001)。结论:PSA与FT的比率是表达不同生物学模式并评估不同组前列腺癌患者的增长率参数。我们认为,本研究的结果可能在理解,评估和计划前列腺癌研究中具有广泛的应用,包括基础科学,筛查,评估疾病风险,预测计划的涉及生化复发的治疗后的疾病分期以及自然病史,进展,激素难治性前列腺癌和疾病特异性生存。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号